Skip to search formSkip to main contentSkip to account menu

RPC1063

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

ozanimod

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Sphingosine-1-phosphate Receptor Modulators in Multiple Sclerosis
The introduction of oral disease modifying therapies has transformed the treatment landscape for patients with multiple sclerosis… 
2018
2018
Ozanimod (RPC1063) Reduces Plasma Levels of Neurofilament Light Chain (NfL) in Patients With Relapsing Multiple Sclerosis (RMS): Results From RADIANCE Part A, a Randomized, Placebo-Controlled, Phase…
Objective: To evaluate plasma NfL levels in patients with RMS participating in RADIANCE Part A. Background: Ozanimod, a once… 
2015
2015
Digestive Disease Week.
Digestive Disease Week (DDW) 2015 will take place in Washington, DC, from May 17 to 19. With more than 400 scientific sessions… 
2014
2014
Pharmacokinetics and Pharmacodynamics of RPC1063 and Its Metabolites in Healthy Adult Volunteers (P1.211)
OBJECTIVE: Evaluate the clinical pharmacokinetics (PK) and pharmacodynamics (PD) of RPC1063 and its metabolites. BACKGROUND… 
2014
2014
Absence Of A Relevant Effect On Cardiac Repolarization In A QT/QTc (TQT) Study of RPC1063, A Novel, Selective S1P1 Receptor Agonist, In Healthy Adult Volunteers (P2.229)
Objective: Assess whether RPC1063 increases the corrected QT (QTc) interval compared to placebo (PBO). Background: RPC1063 is an… 
2014
2014
P356 Safety and PK results of a thorough QT/QTc (TQT) study of orally administered RPC1063, a novel, selective S1P1 receptor agonist
2013
2013
Metabolites of RPC1063 Contribute to In Vivo Efficacy (P05.157)
OBJECTIVE: Identify metabolites of RPC1063 and determine their activity in vitro and in vivo. BACKGROUND: RPC1063 is a potent… 
2013
2013
Safety and Tolerability of Orally Administered RPC1063, a Novel S1P1 Receptor Modulator, in Healthy Adult Volunteers, Results of a Phase 1 Study (P01.178)
OBJECTIVE: To assess safety and tolerability of oral RPC1063 as single and multiple daily doses in healthy adults. BACKGROUND… 
2013
2013
The Preclinical Safety Profile of RPC1063, a Selective and Potent Sphingosine 1-Phosphate 1 Receptor (S1P1R) Agonist (P01.158)
OBJECTIVE: Evaluate the preclinical safety profile of the selective S1P1R agonist RPC1063. BACKGROUND: RPC1063 is being developed… 
2013
2013
Sa1221 Rpc1063, a Potent, Selective S1P1 Receptor Modulator, Is Active in a Therapeutic IBD Model and Exhibits Favorable PK/PD Properties in Healthy Volunteers
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)